Navigation Links
New Study Confirms Health Benefits of Pecorino Romano Cheese
Date:12/2/2009

NEW YORK, Dec. 2 /PRNewswire/ -- The Universities of Sassari and Cagliari (Sardinia - Italy) in conjunction with a team of doctors from the United States, announced today the results of a six-year long research study confirming that Pecorino cheese contains high amounts of CLA (Conjugated Linoleic Acid), an Omega-6 polyunsaturated fatty acid naturally found in certain food groups, and which shows bioactive properties for humans.

The study, conducted in Sardinia, Italy from 2003 to 2009 by Dr. Anna Nudda, (University of Sassari, Italy) and Prof. Sebastiano Banni (University of Cagliari, Italy), along with Dr. Mark McGuire, a Professor in Lactation Biology and on faculty at the University of Idaho; and Dr. Shelley McGuire, an associate professor of nutrition at Washington State University, confirm the health benefits of CLA, including reducing fat, suppressing diabetes, preserving muscle tissue and inhibiting tumor growths on the skin, mammary glands and stomach.

CLA is found primarily in milk and dairy products and in the meat of ruminants - sheep, goats, lamb, cattle. Results are highest when ruminants are fed on fresh grass. It is the grazing grass that gives the end product its unique nutritional and therapeutic properties. Usually Pecorino Romano cheese presents 3-5 times higher CLA compared to cow's cheeses.

This team's research confirms the regular, ongoing consumption of pecorino cheese, as part of a balanced and calorically correct diet, contributes a set of bioactive elements capable of significantly reducing the risk factors associated with eating habits in Western countries. Such as cardiovascular diseases, the enhancement of the immune defenses, the proven anti-inflammatory and cancer-fighting properties.

Preliminary results on a study carried out by the research group of Banni and coll. of the University of Cagliari, Italy, showed that intake of 90 g of Pecorino cheese enriched with CLA (2.5% of total fat) for three weeks decreased plasma LDL and decreased the BMI in human (9M and 11F) slightly hypercholesterolemic.

On the other hand, intake of 45 g of Pecorino cheese enriched with CLA for three weeks in humans did not change LDL, HDL and TC.

Why Pecorino cheese? Grass fed sheep produce a high level of CLA. It is the grazing grass that gives the product its unique nutritional and therapeutic properties. In Sardinia, a region where more than 50% of the farmland is used as pastures, the sheep are fed more than 80% of daily intake with fresh grass, and the livestock techniques used guarantee respect of the animals and their wellbeing.

High amounts of combined linoleic acid are a natural byproduct, and not produced through sophisticated, artificial processes or through genetic modifications. The more the sheep feed on grass pasture, the greater the concentration of unsaturated fatty acids in the Omega-3 family and CLA in products made from their milk. Obviously these benefits are added to the other common benefits of milk, such as the presence of calcium and branched amino acids that are especially important in combating osteopenia or osteoporosis in post-menopausal women and in combating overweight and obesity. Pecorino Romano cheese can be eaten even by those who are lactose intolerant. In addition, to protecting the coronary arteries and protecting against arteriosclerosis, CLA has important immunostimulant, anti-tumor, antioxidant and anti-diabetic properties.

CLA was first revealed by Dr. Michael Pariza at the University of Wisconsin, Madison, in the late 1980s. It was later found that the conjugated isomer was present in uncooked beef and originates from bacterial sources in ruminant animals (Chin et al. 1992). CLA was eventually shown to be not only anticarcinogenic, but also to suppress atherosclerosis, diabetes, and formation of adipose tissue (it may suppress obesity). Early studies showed that CLA would inhibit tumorigenesis in the skin (Ha, Grimm, and Pariza 1987), mammary glands (Ip et al. 1991) and stomach (Ha, Storkson, and Pariza 1990) of experimental animals treated with specific carcinogens.

A double-blind, randomized, placebo-controlled study, published in the December 2000 issue of the Journal of Nutrition found that CLA reduces fat and preserves muscle tissue. An average reduction of six pounds of body fat was found in the group that took CLA, compared to a placebo group. Dr. Michael Pariza, who conducted the research on CLA with the University of Wisconsin-Madison, reported in 2000 to the American Chemical Society that "It doesn't' make a big fat cell get little. What it rather does is keep a little fat cell from getting big."

The group consisted of 71 overweight dieters. When they stopped dieting, and gained back weight, those taking CLA "were more likely to gain muscle and not fat". In a separate study conducted at Purdue University in Indiana, CLA was found to improve insulin levels in about two-thirds of diabetic patients, and moderately reduced the blood glucose level and triglyceride levels.

SOURCE Pecorino Romano


'/>"/>
SOURCE Pecorino Romano
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. High-risk women reluctant to take tamoxifen to prevent breast cancer, U-M study finds
2. Alcohol companies target youths with magazine ads, new study shows
3. Hospital price transparancy laws in California fall short, study finds
4. Childhood Lead Exposure Causes Permanent Damage: Study
5. Study shows modest improvement in advanced lung cancer overall survival rates
6. Targeted Testing Receives Favorable Reviews On PADDS, Begins Nationwide Research Study On The Target Tests of Executive Functioning-OV
7. New American Meditation Institute Study Reports Wide-Ranging Health Benefits from Meditation and Yoga
8. Brain scan study shows cocaine abusers can control cravings
9. Study shows new brain connections form rapidly during motor learning
10. Psychotherapy Can Boost Happiness More Than Money: Study
11. Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing an ... to overcome a rare and deadly chromosome abnormality. , After struggling since birth ...
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: ... data solutions, today announced that its MyDario product is expected to appear ... listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: